C5 (UK) will be holding its Pharma/Biotech IP Due Diligence conference on October 28-29, 2008 in Amsterdam, Netherlands. The conference will offer presentations on the following topics:
• Current trends in patent reform and how they impact your due diligence;
• Assessing the level of due diligence required and special considerations for complex multi-jurisdictional and multi-party transactions;
• A practical look at drafting the checklist and due diligence team selection;
• Essential valuation issues affecting the diligence review;
• Finding the target's prior licensing, contractual, and third party obligations;
• Freedom to operate: Ensuring the purchaser/licensee has right to commercialize the IP at issue;
• Evaluating the scope, validity, and enforceability of the target's patents;
• U.S. and EU regulatory provisions affecting the due diligence process and updates on regulator enforcement priorities;
• Competition law considerations affecting due diligence;
• How will developments in follow-on biologics and biosimilars impact on due diligence?
• Managing due diligence when dealing with industry/university collaborations and licenses;
• Establishing what venture capitalists expect from the due diligence process;
• Protecting confidentiality, trade secrets, and privilege during a diligence review: A U.S. perspective; and
• Preparing and communicating the due diligence analysis.
An additional post-conference workshop entitled: "Drafting an Effective Due Diligence Report" will be offered in the afternoon on October 29, 2008. In the post-conference workshop, attendees will learn how to draft a comprehensive and effective report of due diligence findings. In particular, the post-conference workshop will focus on the following topics:
• Ascertaining the structure and essential elements of due diligence reports;
• Determining the scope of, and any limitations on, the investigation;
• Drafting the executive summary;
• Presenting the search results and patentability/validity analysis;
• Assessing the scope of available patent protection;
• Addressing any obligations associated with the use of the technology to be transferred;
• Presenting the freedom-to-operate search results and analysis;
• Identifying other risks or problems and stating whether they have been resolved;
• Assessing potential exposure and the chance of the adverse party prevailing in litigation;
• Weighing the effect of any disclaimers and limitations of liability;
• Factoring in risks associated with future products and agreements in the works;
• Noting post-completion recommendations: What the buyer should do once the deal is finalized;
• Knowing what else should be included in (and excluded from) the report; and
• Limiting distribution of the report to preserve confidentiality and privilege.
The agenda for the Pharma/Biotech IP Due Diligence conference can be found here. A brochure for this conference can be requested here.
The registration fee for the conference is £1499 ($2,995). Those registering on or before September 26, 2008 will receive a £100 ($200) discount off the registration fee and those registering on or before August 15, 2008 will receive a £200 ($400) discount off the registration fee. Those interested in registering for the conference can do so here, by calling +44 (0) 20 7878 6888, by faxing a registration form to +44 (0) 20 7878 6896, or by e-mailing Karolina Persson at [email protected].
Patent Docs is a media partner of the C5 Pharma/Biotech IP Due Diligence conference.
Comments